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ABSTRACT
Improved efficacy of neoadjuvant endocrine-targeting therapies in luminal breast 
carcinomas could be achieved with optimal use of pathway targeting agents. In a 
mouse model of ductal breast carcinoma we identify a tumor regressive stromal 
reaction that is induced by neoadjuvant endocrine therapy. This reparative reaction 
is characterized by tumor neovascularization accompanied by infiltration of immune 
cells and carcinoma-associated fibroblasts that stain for phosphorylated ribosomal 
protein S6 (pS6), downstream the PI3K/Akt/mTOR pathway. While tumor variants 
with higher PI3K/Akt/mTOR activity respond well to a combination of endocrine 
and PI3K/Akt/mTOR inhibitors, tumor variants with lower PI3K/Akt/mTOR activity 
respond more poorly to the combination therapy than to the endocrine therapy alone, 
associated with inhibition of stromal pS6 and the reparative reaction. In human breast 
cancer xenografts we confirm that such differential sensitivity to therapy is primarily 
determined by the level of PI3K/Akt/mTOR in tumor cells. We further show that the 
clinical response of breast cancer patients undergoing neoadjuvant endocrine therapy 
is associated with the reparative stromal reaction. We conclude that tumor level and 
localization of pS6 are associated with therapeutic response in breast cancer and 
represent biomarkers to distinguish which tumors will benefit from the incorporation 
of PI3K/Akt/mTOR inhibitors with neoadjuvant endocrine therapy.
INTRODUCTION
More than 70% of breast carcinomas are estrogen 
receptor (ER) and progesterone receptor (PR) positive and 
are thus potentially susceptible to anti-endocrine therapies. 
Neoadjuvant endocrine therapy is increasingly used in 
patients that share clinicopathological characteristics 
such as: high ER and PR, low Ki67, HER-2 negative, 
large tumor size, advanced age [1, 2] or presence of 
comorbidities that preclude surgery. While estrogen 
signaling is a key feature of breast cancer etiology, 
experimental and epidemiological evidence has also 
linked progesterone to breast cancer pathogenesis 
[3, 4]. Antiprogestins are being tested in clinical trials 
as second or third line anti-endocrine therapies in 
advanced or metastatic breast cancer settings, reviewed 
in [5]. Among antiprogestins, mifepristone (MFP) has 
shown considerable potential. MFP binds to PR, allows 
dimerization of the receptor and subsequent binding to 
DNA [6], but prevents recruitment of transcriptional 
coactivators to target genes [7].
More than 50% of ER/PR-positive breast cancers 
contain alterations in at least one component of the PI3K/
Akt/mTOR pathway, and these alterations drive cancer 
growth and also facilitate development of resistance to 
hormone prevention therapies [8, 9]. For these reasons, 
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therapeutic agents that target the PI3K/Akt/mTOR 
pathway have been actively pursued, with several agents 
being tested in phase I to phase III studies in combination 
with endocrine therapy [10–12]. Based on the BOLERO-2 
trial in which the addition of everolimus (RAD001), an 
mTOR inhibitor, improved progression free survival in 
aromatase inhibitor resistant breast cancer, the US FDA 
approved the use of everolimus in combination with 
exemestane in patients with metastastic ER-positive breast 
cancer refractory to aromatase inhibitors [13–17].
The tumor microenvironment comprises a hetero-
geneous population of cells including fibroblasts, 
adipocytes, endothelial and immune cells, and the 
extracellular matrix which serves as a scaffold and which 
provides contextual information for the above-mentioned 
cells [18]. Among these stromal cell types, cancer-associated 
fibroblasts (CAFs) have been identified as important 
promoters of tumor growth and progression [19], as players 
in development of hormone independence [20], and as 
potential therapeutic targets in highly desmoplastic human 
cancers [21]. A number of studies have identified specific 
elements of the tumor microenvironment that contribute 
to tumor proliferation, neovascularization, invasion, and 
metastasis [22, 23]. Moreover, differential gene expression 
from breast tumor stroma can be used to identify gene 
profiles associated with breast cancer outcomes [24]. 
However, the role of the tumor microenvironment in 
therapeutic regression remains unknown.
We have used medroxyprogesterone acetate (MPA)-
induced mouse models of breast cancer [25] to define the 
cellular and molecular mechanisms associated with tumor 
regression following endocrine therapy that have allowed 
us to identify key microenvironmental factors that can 
modulate hormone dependency [26], response to endocrine 
therapy, and to PI3K kinase inhibitors [27]. Here, we 
show that endocrine therapy-induced tumor regression in 
hormone-dependent mammary tumors requires a stromal 
response that is dependent upon PI3K/Akt signaling. 
Our findings have significance for effective therapeutic 
targeting of this common breast cancer subtype.
RESULTS
Inhibition of PI3K/Akt enhances endocrine 
therapy-induced tumor regression in hormone- 
independent mammary carcinomas
The MPA-induced mouse model of ductal ER/PR-
positive breast carcinoma generates hormone-dependent 
tumors that require MPA for growth (C4-HD); over time, 
these tumors give rise to variants that can proliferate without 
exogenous hormone supply and are thus designated as 
hormone-independent (C4-HI) [25]. Both tumor types 
are inhibited by the antiprogestin MFP, but differ in their 
activation of PI3K/Akt pathway: C4-HI tumors display 
higher levels of PI3K/Akt, lower PTEN, and higher response 
to the PI3K inhibitor LY294002, or the mTOR inhibitor 
rapamycin, than to endocrine inhibitors, while C4-HD 
tumors are more responsive to endocrine inhibitors [27]. 
Overactivation of PI3K/Akt pathway by myristoylated Akt1 
in estrogen- or MPA-dependent tumor cells induced ER and 
PR activation and ligand-independent tumor growth affecting 
endocrine therapy sensitivity [28]. Here we investigated the 
role of the stroma in response to PI3K inhibition using this 
tumor model. We found that 48 h treatment of C4-HI tumors 
with the PI3K inhibitor wortmannin (WORT) significantly 
enhanced the response to MFP, showing decreased tumor size 
and cell proliferation, and increased necrosis, accompanied 
by increased tumor stroma and tissue differentiation 
(Figure 1A, 1B). The enhanced tumor regression was 
associated with an increase in α-smooth-muscle actin 
(αSMA)-positive CAFs and in CD31-positive endothelial 
cells (Figure 1C). Moreover, while MFP treatment alone 
increased levels of pS6, these were effectively inhibited in 
mice treated with WORT (Figure 1D).
The additive effect of WORT and MFP was also 
found on isolated C4-HI tumor cells growing on 3D 
Matrigel (Supplementary Figure S1A). As with the 
mouse transplantation experiments, the combination of 
MFP+WORT had greater proapoptotic effect than either 
MFP or WORT alone, as observed by phase microscopy, 
and by acridine orange and ethidium bromide (AO/
BE) (Supplementary Figure S1B) and caspase 3 staining 
(Supplementary Figure S1C). These results confirm that in 
C4-HI tumors, the additive proapoptotic effect of WORT and 
MFP that contribute to regression affects directly tumor cells.
Stromal activation of PI3K/Akt is associated 
with tissue remodeling processes that drive 
therapeutic response in hormone-dependent 
mammary tumors
We next evaluated αSMA- and CD31-positive 
stromal cells as biomarkers of tumor regression in 
hormone-dependent tumors. C4-HD tumors require MPA 
to grow [25] and regressed when the MPA pellet was 
removed or after 48 h exposure to antiestrogens such as 
tamoxifen citrate (TAM) or Fulvestrant (ICI182, 780; ICI), 
although treatment with the antiprogestin MFP induced 
larger tumor shrinkage (Figure 2A). While the tumor 
parenchyma underwent cytostasis, apoptosis and 
necrosis, the stromal tissue showed signs of expansion 
and activation, and the stromal area reflected the 
effectiveness of the antitumor treatments (Figure 2A–2C). 
We detected proliferative and apoptotic cells next to the 
regressive stroma, suggesting that different populations 
of tumor cells coexist within the tumor parenchyma in 
contact with the regressive stroma. With more effective 
therapeutic response, activation of Akt (not shown) and 
S6 (Figure 2D) became almost undetectable in residual 
tumor parenchyma but was substantially increased in the 
tumor stroma.
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Figure 1: Combination of MFP and WORT improves C4-HI tumor regression. C4-HI tumors of 50 mm2 were treated 
with MFP (12 mg/kg/day), WORT (1 mg/kg/day), MFP+WORT, or saline (control) for 48 h. A. Top: Tumor size diminished further by 
MFP+WORT than by MFP or WORT itself. Mitotic cells, necrotic and stromal areas were quantified in H&E. Middle: H&E staining in 
whole FFPE tumor sections reveals greater necrosis (pink areas) after combination therapy. Bottom: High magnification images show 
tissue remodeling with signs of differentiation (arrows show ductal-like structures). B. IHC for Ki67 confirms the quantification of mitotic 
cells. C. IHC for αSMA and IF for CD31. Nuclei were stained in red with PI. Quantification shows that the number of CD31-positive foci 
increased after combination therapy. D. Left: IHC for pS6 in Ser240/244 shows that both tumor and stromal levels diminished with WORT. 
Nuclei were not counterstained with hematoxilyn to evidence pS6 signal. Right: WB revealing total and pS6, and ERK1/2 as a loading 
control. Quantification shows that MFP increased whereas WORT reduced pS6 levels. Bar 100 μm.
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Figure 2: MFP is the endocrine agent that induces the strongest stromal reaction and C4-HD tumor regression. When 
C4-HD tumors reached 50 mm2, MPA depot was removed and mice were treated with ICI (5 mg), TAM (5mg/kg/day), MFP or saline (-MPA) 
for 48 h. +MPA group was sham-operated and treated with saline. A. Top: Final tumor size, % Ki67-positive cells, necrotic and stromal 
areas were quantified in IHC or H&E. Bottom: H&E staining reveals that C4-HD endocrine-treated tumor displayed tissue remodeling with 
intense stromal invasion. B. IHC for Ki67 and caspase 3. Arrows indicate that in residual tumor tissue both proliferative (Ki67-positive) and 
apoptotic (caspase 3-positive) cells were localized to the epithelial edge in contact with the invading stroma. C. Top: Mason’s Trichrome 
(blue: collagen-rich fibrillary stroma; red: parenchymal nuclei) confirmed the composition of regressive stroma. Bottom: IHC for αSMA 
shows intense signal in the regressive stromal edge facing residual tumor. D. pS6 staining after treatment decreased in C4-HD tumor 
parenchyma and increased in tumor stroma. Bar 100 μm.
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To define the early events by which treatment-
induced stromal activation of S6 leads to tumor regression, 
we assessed time-dependent response to MFP treatment 
as it had induced the most powerful effect. The tumor 
inhibitory effect (Figure 3A) was preceded by tissue 
rearrangements, as assessed by histology (Figure 3B) and 
immunostaining (Figure 3C). Cytostasis and apoptosis 
became evident in the epithelial compartment after 6 h 
of MFP (Figure 3A). The stromal reaction, including 
increased stromal area (Figure 3A, 3B), increased number 
of αSMA-positive CAFs (not shown), deposition of 
collagen-I (not shown), and increased number of CD31 
foci (Figure 3C), was evident after 12 h of administration 
of MFP following a time-dependent manner. Labeling 
of blood vessels with fluorescent lectins (Figure 3C) 
confirmed that MFP induced functional new vessels.
Consistent with the results in Figure 2D, as 
C4-HD tumor regression progressed in response to MFP, 
the activation of PI3K/Akt/mTOR pathway was reduced in 
C4-HD tumor parenchyma and increased in tumor stroma 
(Figure 3D). Advancing CAFs are the stromal cells that stain 
for pS6 shortly after MFP therapy. The increase in stromal 
pS6-positive CAFswas time-dependent and elucidates the 
changes on pAKT and pS6 levels detected by western blot 
(Figure 3E). Thus, the increasing stromal component in MFP-
treated tumors accounts for the increased overall pS6 levels.
We found that the rapid stromal reaction as assessed 
by increased CAFs and vasculogenesis was accompanied by 
immune cell infiltration. After 48 h of MFP administration, 
the intratumor presence of macrophages (F480+) and 
lymphocytes CD4+ and CD8+ was confirmed (Figure 
3F). We also observed Ki67-positive stromal cells in the 
periphery and decreased Ki67 positivity in the center of 
the tumor, suggesting proliferative activation of tumor-
associated stromal cells and/or migration and invasion 
of proliferative stromal cells from outside the tumor 
(Figure 3G). Together, the results show that the stromal 
reaction, hours after MFP administration, is associated with 
an increase in neovascularization and tumor cell infiltration.
To evaluate PI3K/Akt/mTOR pathway activation 
in the regression of C4-HD tumors, we used the PI3K 
inhibitor WORT alone or in combination with MFP for 
48 h, finding that WORT interfered with MFP-induced 
tumor reduction and tissue remodeling (Figure 4A). 
At 12 h, WORT effectively inhibited the PI3K/Akt 
pathway in both parenchymal and stromal compartments 
as assessed by immunohistochemistry and western 
blot (Figure 4B). Strikingly, the combination of MFP 
and WORT reduced the apoptosis, tissue remodeling, 
neovascularization and immune cell infiltration caused 
by MFP (Figure 4C, 4D).
These results suggest that C4-HD tumor regression 
induced by MFP requires stromal activation of PI3K/Akt 
signaling and its inhibition interferes with the course of 
tumor regression. Extending the observation to six days of 
treatment revealed a sustained inhibition of MFP response 
when combined with WORT (Figure 4E). Further evidence 
that this was due to a requirement for PI3K/Akt signaling 
was provided by the observation that similar effects were 
found when the mTOR inhibitor rapamycin (RAPA) 
was combined with MFP (Figure 4E; Supplementary 
Figure S2). Although MFP+RAPA still induced necrosis, 
almost no stromal reaction was observed and reduction of 
tumor size was shorter than with MFP alone.
To verify that tumor regression specifically requires 
PI3K/Akt activation in the stroma, we evaluated the 
response of these treatments on C4-HD tumor cells growing 
on 3D Matrigel (Supplementary Figure S3A), finding again 
that MFP was the most effective treatment for decreasing 
Ki67 and increasing caspase 3 staining (Supplementary 
Figure S3B, S3C). However, in isolated C4-HD cells, 
WORT did not interfere with MFP-induced cytostasis or 
apoptosis (Supplementary Figure S3B, S3C). Thus, the 
unfavorable effect of WORT on endocrine-induced C4-HD 
tumor regression was not due to a direct effect on tumor 
cells, but rather due to its effect on the tumor stroma itself. 
These results demonstrate the existence of a critical stroma-
dependent tumor regression mechanism that is suppressed 
when PI3K/Akt signaling is inhibited.
The level of PI3K/Akt pathway activation in 
tumor cells determines the extent of stromal 
reaction as well as cell viability in response to 
therapy
Therapy-induced stromal pS6 was observed in C4-
HD (Figure 2D) but not in C4-HI (Figure 1D) tumors. To 
determine the effect of intrinsic tumor heterogeneity on the 
stroma-dependent tumor regression process, we evaluated 
other variants of the MPA-induced model. In tumor 
variants that show low levels of parenchymal pS6 when 
grown as allografts (Figure 5A), MFP-induced tumor 
reduction involves stromal remodeling, αSMA expression 
and pS6 increase, and MFP-induced tumor regression 
was impaired by WORT (Figure 5C). By contrast, in 
tumor variants that display high levels of parenchymal 
pS6 when grown as allografts (Figure 5B), MFP-induced 
tumor reduction involves stromal remodeling with αSMA 
expression, decreased parenchymal pS6, and little stromal 
pS6. In this case, tumor regression was enhanced by the 
combination of MFP and WORT (Figure 5C). These 
results indicate that the differential response to MFP is 
related to basal PI3K/Akt and pS6 levels rather than to 
MPA-dependent status.
To assess the dependence of the stromal response 
on endocrine targeting tumor reduction in human breast 
cancer cell models, we employed T47D and IBH-6 cells 
expressing vector only (Acl4) or expressing an activated 
variant of Akt1 (myristoylated Akt1, myrAkt1) (Figure 6A). 
We used RAPA to overcome the constitutive activation of 
Akt1 due to the myrAkt1 plasmid. In proliferation assays 
using the IBH-6 cell series, the antiestrogen ICI showed 
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Figure 3: Time course and cellular mechanisms involved in stromal reaction in C4-HD tumors. C4-HD tumors were 
treated with MFP for 6, 12, 24 or 48 h. A. Quantification of tumor size (% of pretreatment size), % Ki67-positive cells, caspase 3 and 
stromal indexes. Tumor’s shrinkage, cytostasis, apoptosis and stromal area increased after MFP treatment in a time-dependent fashion. B. 
H&E staining shows tissue remodeling. C. Top: IF for CD31 with nuclei stained in red. Bottom, left: quantification of CD31 foci. Bottom, 
right: labeling with fluorescent lectins. D. IHC shows pS6-positive advancing CAFs after MFP treatment. E. WB reveals total and pAkt 
in Ser473, pS6, and ERK1/2. MFP induced time-dependent Akt and S6 activation. F. IF for F480, CD4 and CD8. G. IHC for Ki67 shows 
positive cells in tumor’s periphery and center. Bar 100 μm.
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Figure 4: Inhibition of PI3K/Akt/mTOR pathway interferes with the stromal reaction induced by endocrine therapy 
in C4-HD tumors. C4-HD tumors were treated for 48 h with MFP, WORT or the combination. A. Left: MFP-treated tumors showed 
smaller size compared to WORT or MFP+WORT-treated tumors. Right: H&E staining reveals greater tissue remodeling in MFP-treated 
tumors. B. Top: IHC for pS6 shows that WORT inhibited MFP-induced levels. Bottom: WB revealing total and pS6, and ERK1/2. C. IHC 
shows that after 12 h of treatment, WORT reduced Ki67 and induced caspase 3 to a lesser extent than MFP. D. IHC for αSMA and IF for 
CD31 and F480, show that MFP, but not WORT, affected stromal area, number of CD31 foci and macrophages infiltration. E. Left: C4-HD 
tumor sizes after 6 days of treatment with WORT or RAPA (5 mg/kg/day). Combination with WORT or RAPA significantly impaired MFP-
induced regression. Right: Representative photographs of treated tumors. Bar: 100 μm.
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a stronger inhibition of proliferation than RAPA in vector 
control cells, whereas RAPA was more effective than ICI 
in Akt1-expressing cells (Figure 6B). We have previously 
shown that MFP inhibits T47D wild type xenograft growth 
[29, 30]. Here we found that orthotopic xenografts of T47D-
Acl4 cells showed significant therapeutic response to MFP 
or MFP+RAPA but not to RAPA itself (Figure 6C), while 
xenografts of T47D-myrAkt1 cells were strongly inhibited 
by RAPA alone or RAPA combined with MFP, but not 
with MFP alone (Figure 6D). In T47D-Acl4 tumors, MFP 
induced strong tissue remodeling and neovascularization 
associated with tumor shrinkage (Figure 6C). By contrast, 
in T47D-myrAkt1 tumors, RAPA was required for induction 
of necrosis and tumor shrinkage (Figure 6D), while MFP did 
not induce tissue remodeling. As expected, pS6 levels were 
higher in T47D-myrAkt1 (Figure 6D) than in T47D-Acl4 
tumors (Figure 6C) and were severely diminished by RAPA. 
Finally, pS6-positive CAFs were induced by MFP in T47D-
Acl4 but not in T47D-myrAkt1 tumors (Figure 6C, 6D).
Together, our findings demonstrate that activation of 
S6 in tumor cells is prognostic of therapeutic response in 
diverse models of breast cancer and represents a potential 
biomarker to distinguish for which tumors combination of 
PI3K/Akt/mTOR inhibitors with anti-endocrine therapies 
would be beneficial, and for which they could have the 
potential to be detrimental.
Correlation between stromal pS6 and αSMA 
suggests a modulatory effect of PI3K/Akt 
pathway in the therapeutic response of human 
breast cancer
To assess how these pathways impact human 
breast cancer treatment response, we evaluated breast 
tumor samples from a set of 24 women who received 
neoadjuvant endocrine therapy at the Mayo Clinic (cohort 
characteristics in Table 1). We analyzed the type and 
grade of stromal reaction in the post-treatment samples, 
Figure 5: Tumor level of PI3K/Akt pathway determines the extent of stromal reaction in response to therapy. A & B. 
When C7–2-HI, 32–2-HI, 59-HD or 59–2-HI tumor variants reached a size of 50 mm2 (arrows), mice were treated with MFP or saline 
solution (control). Tumors were treated for 6 days, except for 32–2-HI tumors that were treated for only 6 or 24 h since its response is 
extremely fast. Top: Growth curves show that MFP caused tumor regression. For 32–2-HI bar graph represents tumor size after 24 h of 
treatment. Bottom: IHC for αSMA and pS6 previous to MFP treatment shows that parenchymal pS6 levels were lower in C7–2-HI and 
32–2-HI than in 59-HD and 59–2-HI tumors. After MFP treatment, pS6 increased in the stromal compartment in C7–2-HI and 32–2-HI 
tumors, and it reduced in the parenchymal compartment in 59-HD and 59–2-HI tumors. C. Left: C7–2-HI and 59–2-HI tumors were 
transplanted simultaneously in the same mouse in opposite flanks and when tumors reached a size of 50 mm2, treatments started (day 0) 
with MFP, WORT or the combination, and continued for 6 days. Right: Tumor sizes show that C7–2-HI tumors responded poorly to WORT 
whereas 59–2-HI tumors reduced tumor size after WORT treatment. Bar: 100 μm.
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assessing collagen-I (not shown), αSMA, CD31, and pS6 
score in the parenchyma and in the stroma (Figure 7A). To 
evaluate the therapeutic response, we compared tumor size 
before starting therapy and immediately before surgery. 
The clinical response to treatment correlated significantly 
with stromal αSMA (Figure 7B). We also found that while 
αSMA, pS6 and CD31 were associated in areas where 
the stroma increased and the tumor regressed (Figure 7A 
inserts), CD31 levels were not significantly correlated with 
αSMA or pS6 scores in the overall sample. Strikingly, 
stromal but not parenchymal pS6 correlated significantly 
with αSMA (Figure 7B) and in quiescent or fibrotic stroma 
pS6 was low or absent (Figure 7A). Furthermore, actively 
regressive tumor areas showed that αSMA, pS6 and CD31 
were mainly localized in the advancing stroma (Figure 7A 
inserts). While these results are somewhat limited by 
considerations of sample size and heterogeneity of patient 
treatment regimens, our findings are supportive of our 
model that tumor regressive processes in humans also 
involve stromal PI3K/Akt/mTOR pathway activation.
Figure 6: Tumor cell level of PI3K/Akt pathway determines response to therapy. A. WB from cellular extracts revealing PI3K, 
Akt, total and pS6, and ERK1/2. Akt antibody detected both the endogenous and the myristoylated deleted myrAkt1variant. MCF-7 cells 
were used as a control. B. IBH-6-Acl4 and IBH-6-myrAkt1 cells were treated with ICI 1 μM, RAPA 0.1 μM or the combination for 6 days, 
and final cell number was counted. C&D. T47D-Acl4 and T47D-myrAkt1 cells were injected into NOD/SCID mice. Tumors of 30 mm2 were 
treated with MFP, RAPA (5 mg/kg/day) or the combination, and continued for 6 days. Top, left: Tumor sizes expressed as % of pretreatment 
size. T47D-Acl4 tumors responded mainly to MFP whereas T47D-myrAkt1 tumors responded mainly to RAPA. Representative photographs 
(right) and H&E (center) of control and treated tumors. Inserts: T47D-Acl4 tumors show MFP-induced blood vessels. Bottom: IHC for pS6 
shows that stromal levels were higher in T47D-Acl4 than in T47D-myrAkt1 tumors after MFP treatment. Bar: 50 μm.
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In another set of 18 human samples naïve of any 
treatment (cohort characteristics described in Table 2), 
αSMA was present in fibroblasts, myoepithelial cells 
and vascular structures (Figure 7C). Epithelial neoplastic 
cells showed pS6-positive staining in 13 of 18 samples 
(65%), but pS6 was totally absent in the stroma in these 
samples. These findings support our model that stromal 
pS6 discriminates, at an early stage of treatment, which 
subset of patients has activated PI3K/Akt pathway and 
could therefore benefit from an anti-endocrine/anti-PI3K/
Akt combination therapy.
DISCUSSION
Here we defined a novel role of the stromal reaction 
in breast tumor regression after anti-endocrine therapy. 
We found that stromal expression of pS6 may represent 
a biomarker for the benefit of incorporating PI3K/Akt/
mTOR inhibitors into neoadjuvant endocrine therapies. 
Using mouse models of ER/PR-positive breast carcinomas, 
orthotopic xenografts of T47D human breast cancer cells, 
and clinical samples from breast cancer patients undergoing 
neoadjuvant endocrine therapy, we found that the intrinsic 
Table 1: Patient characteristics for treated-breast carcinomas from Mayo Clinic
Patient # Age (years) Tumor size (cm) Node Treatment Histopathological data and prognostic factors
Pre-
treatment
Post-
treatment
Drug Days Subtype Grade ER PR HER-2
1 83 5, 1 7, 5 - anastrozol 153 ibc NST moderate + + -
2 66 7, 1 7 - anastrozol 156 ibc NST moderate + + -
3 59 4 2, 9 + exemestane 125 ibc NST moderate + + -
4 57 8 8, 8 + anastrozol 123 ibc NST high + + -
5 67 10 4, 5 + anastrozol 163 ibc NST moderate + + +
6 82 2, 4 1, 8 - letrozol 43 ibc NST moderate + + -
7 71 2, 3 1, 9 - anastrozol 120 ibc NST moderate + + -
8 70 n/a 12, 5 + letrozol 347 ibc NST moderate + + -
9 64 2, 5 1, 7 + letrozol 205 ibc NST moderate + + -
10 83 7 6, 8 + anastrozol 251 ibc NST moderate + + -
11 57 6, 2 8, 1 + anastrozol 157 ilc moderate + n/a -
12 54 5, 2 4, 8 + exemestane + goserelin 281 dcis low + + -
13 67 5, 2 3, 8 + letrozol 166 ibc NST high + + n/a
14 70 2, 4 1, 5 - anastrozol 105 ibc NST moderate + + -
15 57 10 4, 3 + anastrozol 273 ibc NST moderate + + -
16 75 2, 5 2, 3 + letrozol 119 ibc NST moderate + + -
17 77 n/a 2, 4 - anastrozol 503 ibc NST moderate + + n/a
18 95 1, 6 1, 7 + tamoxifen 98 dcis moderate + + -
19 76 4, 2 1, 8 - anastrozol 56 ibc NST low + + n/a
20 77 4 3 + tamoxifen 107 ibc NST low + + n/a
21 62 6, 2 5, 8 + anastrozol 77 ibc NST moderate + + -
22 72 4, 9 0, 8 - anastrozol 155 ibc NST low + + -
23 68 8 7, 2 - anastrozol 97 ibc NST moderate + + -
24 65 3 2, 5 + anastrozol 126 ibc NST moderate + + -
*dcis: ductal carcinoma in situ, Ibc NST: invasible breast carcinoma of not special type, ilc: invasive lobular carcinoma, 
n/a: data not available
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tumor heterogeneity for PI3K/Akt/mTOR activation as 
assessed by S6 protein phosphorylation is associated with 
therapeutic response. Stromal pS6 is present exclusively 
after therapy and is absent in non-treated tumors or in 
endocrine-treated tumors with a poor reactive stroma. We 
suspect that the presence of pS6 in stromal or in parenchymal 
compartments after neoadjuvant endocrine therapy is related 
to particular mechanisms involved in tumor regression. Thus, 
Figure 7: αSMA correlates with tumor reduction and stromal pS6 after neoadjuvant endocrine therapy. Breast tumor 
samples were classified according to the percentage of tumor reduction, between no response (increase or no change in tumor mass) n = 4, 
intermediate response (less than 30% reduction) n = 12, or better response (more than 30% reduction) n = 8. A. H&E and IHC for αSMA, 
pS6 and CD31 in one representative tumor of each group. The amount and intensity of αSMA and stromal pS6 label increased according to 
% of tumor reduction. Inserts: αSMA, pS6 and CD31 were mainly localized in active areas of advancing stroma. B. The entire cohort of 24 
patients was distributed for the graph in terms of tumor reduction with the arbitrary cut off of 30% and analyzed as a whole for correlation 
between the three parameters. Stromal αSMA correlated significantly with stromal pS6 score (p = 0.039, Spearman Rho) and with the % of 
tumor reduction (p = 0.036, Spearman Rho). C. H&E and IHC for αSMA and pS6 in tumor areas of one representative non-treated patient, 
showing the staining of pS6 in the parenchyma and its absence in the stroma. Bar: 100 μm.
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evaluation of parenchymal and stromal expression of pS6 
early in treatment may identify which patients would benefit 
from combining PI3K/mTOR inhibitors with neoadjuvant 
endocrine therapies, and more critically, for which patients 
this combination would be potentially detrimental. Future 
studies are necessary to validate this hypothesis and its 
possible relevance for selecting patients for PI3K/Akt/
mTOR pathway-targeting drugs in clinical practice.
In both pre-clinical and clinical settings, we found 
that the stromal reaction associated with activation of 
αSMA and deposition of collagen-I is linked to better 
therapeutic outcomes. We further found that in the mouse 
model, MFP-induced formation of functional new vessels 
relates to tumor cell infiltration of pS6-positive CAFs and 
immune cells, likely representing a crucial role of stromal 
pS6 in the remodeling and healing processes that take 
place during early stages of tumor regression. Previous 
reports have suggested that human breast CAFs can 
directly promote angiogenesis through the expression of 
stromal cell-derived factors [31] and that CAFs promoted 
macrophage recruitment, neovascularization, and tumor 
growth in a mouse model of squamous skin carcinogenesis 
[32]. We speculate that mesenchymal fibroblasts could 
be the key cell type responsible for the tumor regressive 
stromal reaction, but further studies are necessary to fully 
evaluate this hypothesis. We found that in tumor variants 
in which there is low intrinsic tumor level of PI3K/Akt/
mTOR relative to that found in the stroma, blockage of 
pS6 activation through the use of PI3K/mTOR inhibitors 
interferes with MFP-induced neovascularization, immune 
cell infiltration and tumor regression. However, in tumor 
variants with a high intrinsic tumor level of PI3K/Akt/
mTOR, MFP as a single agent did not induce tumor 
regression, and its combination with PI3K/mTOR 
inhibitors is required to induce a therapeutic response. 
Since in human samples we found that actively regressive 
Table 2: Patient characteristics for non-treated breast carcinomas from CORI Cancer Center
Patient # Age (years) Tumor size 
(cm)
Node Histopathological data and prognostic factors
Subtype Grade ER (%) PR (%) HER-2 Ki-67 (%)
1 42 2 + ibc NST moderate 80 40 - 40
2 n/a 2 + ibc NST low 90 20 - 20
3 72 2, 5 - ibc NST high 80 10 - 10
4 78 n/a n/a ibc NST high 70 10 - 10
5 n/a 1 n/a papilary carcinoma n/a 90 30 - 30
6 n/a 2 n/a ibc NST moderate 90 30 - 30
7 64 2 n/a ibc NST moderate 80 60 - 60
8 n/a 1, 3 n/a ibc NST moderate 30 2 - 2
9 36 n/a - papilary carcinoma high 80 20 - 20
10 59 0, 4 n/a ibc NST moderate 90 30 - 30
11 n/a 1, 7 n/a ibc NST high 90 30 - 30
12 45 1, 7 n/a ibc NST high 70 5 - 5
13 n/a n/a n/a apocrine carcinoma high 70 5 - 5
14 73 n/a n/a ibc NST high 90 10 - 10
15 n/a 2 n/a mucinous carcinoma low 100 60 - 60
16 66 n/a + ibc NST moderate 90 5 - 5
17 n/a 2, 3 + ibc NST moderate 90 5 - 5
18 63 1, 5 - ibc NST moderate 30 60 - 60
*ibc NST: invasive breast carcinoma of not special type, n/a: data not available.
*% (positive cells/total number of cells)
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tumor areas of advancing stroma stained positive for 
αSMA, pS6 and CD31, our results in the mouse model 
could provide mechanistic insight into how stromal pS6 
activation occurs and how it contributes to breast tumor 
regression after endocrine therapy.
Variations in breast cancer-associated stromal 
histology have been described from predominantly cellular 
(fibroblasts/myofibroblasts) to fibrillar (dense collagenous 
stroma) subtypes [33]. Such stromal variations are associated 
with differential paracrine activation by growth factors 
and cytokines. Recent studies have evaluated variations 
in tumor stroma as a predictor of outcome in breast 
cancer patients [34], finding that a higher ratio of tumor to 
stroma is associated with recurrence and poorer long-term 
survival. Another recent study evaluating tumor stroma 
after endocrine therapy in breast cancer [35] found that 
molecular differences between invasive lobular cancer (ILC) 
and infiltrating ductal carcinomas (IDCs) are maintained 
following endocrine treatment. It is becoming clear that 
detailed analyses of tumor parenchyma and stroma, as well 
as their interactions will be required to develop therapies 
that target the tumor microenvironment [21, 36–40]. In this 
context, our results have particular relevance by providing 
insight into stromal biomarkers of antitumor efficacy that 
are evident soon after treatment begins, which is lacking 
in current therapeutic protocols. The parameters that we 
identified here (αSMA and pS6) are easily quantified by 
pathological examination using normal clinical procedures.
While endocrine therapies can be initially effective 
for ER/PR breast cancer patients, acquired or de novo 
resistance and subsequent recurrence remain significant 
clinical problems. Pre-clinical in vivo studies have recently 
been developed [41, 42] and an improved understanding 
of the interaction of endocrine and PI3K/Akt/mTOR 
inhibitors in neoadjuvant settings is necessary to break 
down the heterogeneity in responses to target therapy as 
reported in the clinic [13]. We assessed model systems 
and human breast tumor samples to dissect how stromal 
activation of PI3K/Akt affects response to endocrine 
therapies. Our findings demonstrate that activation level 
of S6 in tumor cells is prognostic of therapeutic response 
and could be relevant to explore the involvement of PI3K/
Akt/mTOR targeting therapy to avoid or delay hormone 
independence and consequently endocrine resistance. The 
molecular mechanisms that contribute to tumor regression 
after therapy, conferring the response of the tumor cells 
to MFP and the induction of S6 phosphorylation in the 
stromal cells, remain to be defined. The authors speculate 
that these mechanisms relate more with a wound healing 
process than to tumor growth events. Further experiments 
are being performed to examine the molecular interactions 
between tumor cells and stromal cells during tumor 
regression after therapy. Also, longer-term studies will 
be necessary to determine if the more effective methods 
for inducing tumor regression identified in our study also 
confer reduced rates of tumor relapse.
It has been proposed that tumors with mutations at 
the catalytic p110α subunit of PI3K (PIK3CA mutations) 
that may confer activation of the PI3K/Akt/mTOR 
pathway are more sensitive to PI3K/mTOR inhibitors 
[43], although the prognostic value of PIK3CA mutations 
in ER-positive breast cancer is still controversial 
[44–47]. The effect of PI3K/mTOR inhibitors has yet 
to be validated through reliable biomarkers of efficacy 
[48]. Phosphorylated S6 and its kinase p70S6K also have 
been proposed to predict tamoxifen resistance [49]. The 
striking finding in our pre-clinical models, supported by 
our results with human breast cancer biopsies, is that 
pS6 is highly expressed in invading and reactive stroma 
after therapy. It has been reported that stromal pS6 
increased in the fibroblasts embedded within the tumors 
in Caveolin-1 knock out mice [50] and the authors related 
that finding with angiogenesis and with breast tumor 
hormone-independent growth. The authors also reported 
these effects can be reduced by RAPA and suggested the 
involvement of the stromal mTOR pathway on blood 
vessel formation and tumor growth in Caveolin-1–
deficient tumors. Strikingly, here we propose that the 
proliferative stroma with activated mTOR signaling could 
also be a good prognostic indicator of the tumor regressive 
process in a particular tumor context. Then, pS6 is a 
potential early biomarker that could predict better clinical 
outcome after endocrine therapy in those tumors with a 
high percentage of stained stromal cells. On the basis of 
the results present here, we speculate that tumor level and 
localization of PI3K/Akt/mTOR pathway activation before 
neo/adjuvant therapy can be used to predict which patients 
will benefit with a combination therapy with PI3K/mTOR 
inhibitors and which patients will not. For those in the 
latter category, it may be that endocrine therapy only 
should be recommended.
An increase in microvasculature and tumor infiltration 
by MFP was recently reported in other MPA-induced tumors 
as well as in T47D xenografts [30]. Our results are consistent 
with those reported by Nakasone et al., who found that the 
microenvironment contributes critically to the response 
to chemotherapy via regulation of vascular permeability 
and immune cell infiltration [51]. Furthermore, we show 
here that WORT interferes or potentiates the MFP-induced 
neovasculature in C4-HD or C4-HI tumors, respectively. This 
dual effect of PI3K in angiogenesis was already observed 
both in normal tissues and in cancers [52, 53]. Furthermore, 
it has been reported in mice that inhibition of PI3K could 
normalize vascular structure and increased perfusion of breast 
tumors improving delivery of doxorubicin [54]. Even though 
the mechanisms by how the stromal activation interact with 
endocrine therapies remains to be demonstrated, we speculate 
that in some type of tumors pS6 stromal activation could 
drive stromal reaction involving angiogenesis that contributes 
to tumor infiltration of immune cells and also to tumor 
shrinkage through improvement of drug delivery. Further 
studies will be necessary to assess this possibility.
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A limitation of the MPA-induced murine model used 
here is that it is a progesterone-driven model. However, 
endocrine sensitivity or resistance coexists for both 
antiprogestins and antiestrogens [25], supporting the use 
of this model as appropriate for studying ER/PR-positive 
disease. Another limitation of our study is that we used 
ER/PR-positive T47D cells that have oncogenic mutations 
in PIK3CA [55]. Nevertheless, introduction of myrAkt1 
construct in T47D cells still increases PI3K/Akt/mTOR 
pathway. Referring to human samples, different endocrine 
therapies have been used in the cohort of 24 patients 
available for this study. Considering that each therapy 
could have different mechanisms of actions and resistance, 
a more comprehensive study that include patients from 
multiple clinical centers could provide a more complete 
assessment. Furthermore, studies considering clinical, 
histopathological and molecular parameters should be 
done in biopsies before and after treatment to validate the 
potential role of pS6 in the prediction of therapy efficacy.
CONCLUSIONS
Our findings demonstrate that the stromal reaction 
accompanied by αSMA increase that occurs early in tumor 
regression resembles a healing process that is indicative 
of overall therapeutic response. We find that stromal 
and parenchymal phosphorylated ribosomal protein S6 
(pS6) downstream PI3K/Akt/mTOR pathway constitutes 
potential biomarkers of targeting therapy efficiency. 
Moreover, we show that PI3K/mTOR inhibition in 
combination with endocrine targeting therapies represent 
a useful approach only in tumors that have high levels of 
PI3K/Akt/mTOR in the parenchymal compartment. The 
current challenge will be to evaluate the generalizability of 
pS6 levels and localization as biomarkers to design, guide 
and monitor treatment strategies for breast cancer patients.
MATERIALS AND METHODS
Animals
Two-month-old virgin female BALB/c mice 
from the University of La Plata and NOD/LtSz-scid/IL-
2Rgamma null mice (NSG) from The Jackson Laboratory 
were bread at IByME (Animal Facility). Animal care and 
manipulation were in agreement with the International 
Guide for the Care and Use of Laboratory Animals [56].
Tumors from MPA-induced model of breast 
cancer
The MPA murine model of breast cancer was 
formerly established in BALB/c mice reviewed in [25]. 
For details about drugs and treatments see Supplementary 
Material 1.
Cell lines and establishment of tumor xenografts
IBH-6 [28, 57] and T47D (ATCC) human breast 
cancer cells were stably transfected with an empty Acl4 
retroviral vector, or a myristoylated human Akt1-Δ4–129 
(myrAkt1) construct, as described in [28]. Cell counting 
and xenograft implantation were previously described 
[29, 30], for more details see Supplementary Material 2.
Human breast cancer tissue samples
Human samples were obtained from a tissue bank 
with no selection criteria. The study on treated samples 
was limitated to the number of available samples of 
breast carcinomas that had been treated with neoadjuvant 
endocrine therapy and undergone surgical resection at 
Mayo Clinic. Written informed consents were received 
from participants prior to inclusion in the study and 
are available in Mayo Clinic and CORI Cancer Center. 
Confidentiality was preserved for the investigators in a 
codified form. Mayo Clinic provided approval for this 
research through its Institutional Review Board. The 
IByME Ethics Committee approved the study with CORI 
Cancer Center.
Histopathological analysis
Tumors were fixed, paraffin-embedded (FFPE) and 
sectioned. The histopathological features of both tumor 
parenchyma and stroma were evaluated in hematoxylin 
and eosin (H&E)-stained slides. Apoptosis, mitosis, 
necrotic and stromal area quantification are described in 
Supplementary Material 3.
Immunohistochemistry (IHC)
FFPE tissues were stained for primary antibodies. 
For details about IHC protocol, Ki67 and caspase 3 
quantification see Supplementary Material 4.
Immunofluorescence (IF)
Tumor sections were analyzed under a Nikon 
Eclipse E800 Confocal Microscope. For details see 
Supplementary Material 5.
Epithelial cell clusters were obtained by differential 
sedimentation from C4-HD and C4-HI tumors as 
previously described [27]. For details about primary 
cultures, IF protocol and indexes quantification see 
Supplementary Material 6.
Western blot (WB)
For details about protocol see Supplementary 
Material 7.
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Statistical analyses
Statistical analyses were performed with the 
GraphPad Prism™ software 5.0 (GraphPad Software, 
Inc.). One way ANOVA followed by Tukey multiple post 
t-test were used to compare means of multiple samples. 
When comparing the means of two different groups, two-
sided Student’s t-test was applied. Tumor growth curves 
were studied using regression analysis, and the slopes 
compared using analysis of variance. Data from patient 
samples was analyzed using SSPN software (IBM) to 
find correlations using Spearman’s Rho test. In all graphs, 
the mean ± SEM are shown. Significant differences 
*, p < 0.05; **, p < 0.01; ***, p < 0.001.
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